OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the increase in clinical pregnancy rate
after administration of a range of single oral doses of OBE001, an oral oxytocin antagonist,
compared to placebo.